Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
2020184 citationsJournal Articlehybrid Open Access
Field-Weighted Citation Impact: 20.00
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial | Researchclopedia